A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

NCT00723957 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG: Ixabepilone, 32 mg/m^2
DRUG: Paclitaxel, 200 mg/m^2
DRUG: Carboplatin (area under the concentration curve [AUC] 6)

Sponsor

R-Pharm